Monopar Therapeutics Inc. (MNPR) has a consensus analyst rating of Buy, based on 13 analysts covering the stock. Of those, 11 recommend buying, 2 recommend holding, and 0 recommend selling.
The analyst consensus price target for MNPR is $121.00, representing a +108.9% upside from the current price of $57.92. Price targets range from a low of $115.00 to a high of $125.00.
